Key result
A simplified clinical scoring model using age, AST, RBC, and platelet count accurately predicted the presence of fibrosis in non-obese NAFLD patients with an AUC of 0.92.
Why the study?
Fibrosis drives nonalcoholic fatty liver disease (NAFLD) progression, motivating the development of a simple clinical scoring system and nomogram to evaluate fibrosis in non-obese NAFLD patients.
Can a simple clinical scoring model based on noninvasive bioindicators predict fibrosis risk in non-obese NAFLD patients?
Observational (n=99)
No
Can a simple clinical scoring model based on noninvasive bioindicators predict fibrosis risk in non-obese NAFLD patients?
Effect estimate: AUC 0.92 (95% CI 0.86-0.97)
A simple, non-invasive clinical scoring model using age, AST, PLT, and RBC can reliably assess the presence of liver fibrosis in non-obese NAFLD patients.
May support noninvasive fibrosis assessment in non-obese NAFLD; leaves open need for prospective validation before adoption.
BACKGROUND: The presence of fibrosis is the main cause of the progression of nonalcoholic fatty liver disease (NAFLD). Our study aims to develop a simple clinical scoring system and nomogram for evaluating fibrosis in non-obese NAFLD patients. METHODS: This retrospective study included 99 non-obese NAFLD patients who underwent liver biopsy in China. The clinical scoring system and nomogram were used to predict the disease progression of NAFLD. RESULTS: Of the 99 non-obese patients with NAFLD, 41 (41.1%) were fibrosis. On multivariate logistic regression analysis, age, alanine aminotransferase(AST), platelet(PLT) and red blood cell (RBC) showed significant association with fibrosis (all P＜0.05). The area under curves (AUC) of the prediction model of fibrosis for non-obese patients established by the above four variables was 0.94 (95% confidence interval (CI):0.89-0.98). Moreover, the AUC of the further simplified clinical scoring model was 0.92 (95%CI 0.86-0.97). High risk group with score greater than or equal to 5, and low risk group with score less than or equal to 2. The nomogram had a good effect in evaluating the risk of fibrosis in non-obese NAFLD patients. CONCLUSION: A simple, easily calculated and non-invasive clinical score can reliably assess the presence of fibrosis in non-obese NAFLD patients. This scoring model complements the deficiency of the prediction system for disease progression in non-obese NAFLD patients, and brings good news for early identification and intervention of these patients.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2023) conducted an observational in Nonobese Nonalcoholic Fatty Liver Disease (n=99). Clinical scoring model (age, AST, RBC, PLT) was evaluated on Prediction of fibrosis (AUC 0.92, 95% CI 0.86-0.97). A simplified clinical scoring model using age, AST, RBC, and platelet count accurately predicted the presence of fibrosis in non-obese NAFLD patients with an AUC of 0.92.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: